CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP

Abstract excerpt

Abstract Mutations in isocitrate dehydrogenases 1 and 2 (IDH) occur in the majority of World Health Organization grade II and III gliomas. IDH1/2 active site mutations confer a neomorphic enzyme activity producing the oncometabolite D-2-hydroxyglutarate (D-2HG), which generates the glioma CpG island methylation phenotype (G-CIMP). While IDH1/2 mutations and G-CIMP are commonly retained during tumor recurrence,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Epigenetics and DNA Methylation
• Share to Glioma Diagnosis and Treatment
• Share to MicroRNA in disease regulation